Novartis raises the temp on Eylea rivalry with head-to-head trial win for Beovu in diabetic macular edema

Regeneron’s anti-VEGF Eylea has long dominated its market, but competitors are looking to dethrone the king — particularly Novartis’ latecomer Beovu. Hampered by prior safety concerns, Novartis has set Eylea directly in its sights with a pair of non-inferiority studies for Beovu that could help it get over the line in macular edema.